Pluri (PLUR) Competitors $4.30 -0.15 (-3.37%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PLUR vs. LXEO, IKT, ALEC, EPRX, BDTX, KRRO, FTLF, NKTX, GLSI, and TARAShould you be buying Pluri stock or one of its competitors? The main competitors of Pluri include Lexeo Therapeutics (LXEO), Inhibikase Therapeutics (IKT), Alector (ALEC), Eupraxia Pharmaceuticals (EPRX), Black Diamond Therapeutics (BDTX), Korro Bio (KRRO), FitLife Brands (FTLF), Nkarta (NKTX), Greenwich LifeSciences (GLSI), and Protara Therapeutics (TARA). These companies are all part of the "pharmaceutical products" industry. Pluri vs. Its Competitors Lexeo Therapeutics Inhibikase Therapeutics Alector Eupraxia Pharmaceuticals Black Diamond Therapeutics Korro Bio FitLife Brands Nkarta Greenwich LifeSciences Protara Therapeutics Pluri (NASDAQ:PLUR) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, analyst recommendations, risk, dividends, profitability and community ranking. Does the MarketBeat Community favor PLUR or LXEO? Lexeo Therapeutics received 28 more outperform votes than Pluri when rated by MarketBeat users. Likewise, 100.00% of users gave Lexeo Therapeutics an outperform vote while only 50.00% of users gave Pluri an outperform vote. CompanyUnderperformOutperformPluriOutperform Votes150.00% Underperform Votes150.00% Lexeo TherapeuticsOutperform Votes29100.00% Underperform VotesNo Votes Does the media prefer PLUR or LXEO? In the previous week, Pluri and Pluri both had 2 articles in the media. Lexeo Therapeutics' average media sentiment score of 1.77 beat Pluri's score of -0.04 indicating that Lexeo Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Pluri Neutral Lexeo Therapeutics Very Positive Is PLUR or LXEO more profitable? Lexeo Therapeutics has a net margin of 0.00% compared to Pluri's net margin of -3,551.49%. Lexeo Therapeutics' return on equity of -57.66% beat Pluri's return on equity.Company Net Margins Return on Equity Return on Assets Pluri-3,551.49% -2,778.13% -83.61% Lexeo Therapeutics N/A -57.66%-48.18% Do institutionals & insiders hold more shares of PLUR or LXEO? 16.6% of Pluri shares are owned by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are owned by institutional investors. 25.9% of Pluri shares are owned by company insiders. Comparatively, 5.3% of Lexeo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Which has higher valuation & earnings, PLUR or LXEO? Pluri has higher revenue and earnings than Lexeo Therapeutics. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPluri$1.03M32.57-$20.89M-$5.53-0.78Lexeo Therapeutics$650K208.89-$66.39M-$3.30-1.24 Which has more volatility & risk, PLUR or LXEO? Pluri has a beta of 0.77, meaning that its stock price is 23% less volatile than the S&P 500. Comparatively, Lexeo Therapeutics has a beta of 0.52, meaning that its stock price is 48% less volatile than the S&P 500. Do analysts prefer PLUR or LXEO? Pluri currently has a consensus target price of $12.00, indicating a potential upside of 179.07%. Lexeo Therapeutics has a consensus target price of $18.50, indicating a potential upside of 352.32%. Given Lexeo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Lexeo Therapeutics is more favorable than Pluri.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Lexeo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14 SummaryLexeo Therapeutics beats Pluri on 13 of the 18 factors compared between the two stocks. Get Pluri News Delivered to You Automatically Sign up to receive the latest news and ratings for PLUR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PLUR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PLUR vs. The Competition Export to ExcelMetricPluriBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$33.68M$3.12B$5.61B$8.62BDividend YieldN/A1.56%5.28%4.17%P/E Ratio-0.7732.9027.1419.96Price / Sales32.57466.20411.83157.63Price / CashN/A168.6838.2534.64Price / Book-10.243.427.064.69Net Income-$20.89M-$72.35M$3.23B$248.14M7 Day Performance-10.04%7.27%2.67%2.39%1 Month Performance-19.10%17.53%8.82%6.05%1 Year Performance-24.83%-17.27%31.44%13.60% Pluri Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PLURPluri2.063 of 5 stars$4.30-3.4%$12.00+179.1%-20.8%$33.68M$1.03M-0.77150Short Interest ↑Gap DownLXEOLexeo Therapeutics3.8101 of 5 stars$4.38+12.9%$18.50+322.4%-74.3%$145.40M$650K-1.3958Gap UpIKTInhibikase Therapeutics1.5004 of 5 stars$1.95-0.5%$6.50+233.3%+22.9%$144.97M$260K-0.736Gap UpALECAlector3.5254 of 5 stars$1.44-3.4%$4.00+177.8%-63.1%$143.99M$88.34M-0.85270Positive NewsShort Interest ↑Analyst RevisionEPRXEupraxia Pharmaceuticals2.3064 of 5 stars$3.97+0.8%$10.50+164.5%+38.9%$142.32MN/A-5.5129BDTXBlack Diamond Therapeutics3.4808 of 5 stars$2.48-3.9%$14.60+488.7%-61.1%$141.02M$70M-1.8690Positive NewsKRROKorro Bio3.5719 of 5 stars$14.85+1.8%$102.43+589.8%-64.8%$139.46M$4.82M-1.5770Positive NewsAnalyst RevisionGap DownFTLFFitLife Brands4.1997 of 5 stars$14.19-0.8%$20.50+44.5%-5.9%$133.26M$63.86M16.7920Short Interest ↑NKTXNkarta3.6623 of 5 stars$1.87-1.6%$14.67+684.3%-69.2%$132.69MN/A-0.99140Analyst ForecastGLSIGreenwich LifeSciences2.2846 of 5 stars$9.45-2.2%$39.00+312.7%-32.1%$126.33MN/A-11.813TARAProtara Therapeutics2.4835 of 5 stars$3.27-2.1%$20.50+526.9%+20.1%$126.16MN/A-1.1630Analyst RevisionGap Up Related Companies and Tools Related Companies Lexeo Therapeutics Competitors Inhibikase Therapeutics Competitors Alector Competitors Eupraxia Pharmaceuticals Competitors Black Diamond Therapeutics Competitors Korro Bio Competitors FitLife Brands Competitors Nkarta Competitors Greenwich LifeSciences Competitors Protara Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PLUR) was last updated on 6/12/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredTrump’s true trade war strategyThe media and financial pundits are all misreading Trump’s actions. They think Trump wants to make Canada t...Porter & Company | SponsoredBig Changes Coming to Social Security?According to legendary investor Louis Navellier... This new Trump move could soon not only save Social Secu...InvestorPlace | SponsoredSHOCKING: Musk's Pentagon Secret Mission...It's about a harrowing message discovered on December 16, 2024: "美国军方暗杀名单" It's the reason President Tru...Behind the Markets | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pluri Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pluri With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PLUR Stock Free PLUR Stock Alerts